This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Omnicell's Rising Costs Affect Bottom Line Amid Competition
by Zacks Equity Research
Soft margin scenario is a headwind for Omnicell (OMCL). The company's strategic endeavors such as portfolio expansion, acquisitions and new market growth persistently escalate expenses.
Myriad Genetics Presents Encouraging EndoPredict Test Data
by Zacks Equity Research
Myriad Genetics (MYGN) forges ahead with initiatives to boost the Molecular Diagnostics portfolio.
NxStage Nx2me Connected Health Improves Home Hemodialysis
by Zacks Equity Research
NxStage Medical (NXTM) consistently looks to expand dialysis platform.
Cooper Companies (COO) Tops Q4 Earnings & Revenue Estimates
by Zacks Equity Research
Cooper Companies (COO) continues to witness impressive results at the CooperVision business segment that delivered strong sales in Q4.
Vertex Kalydeco Study Successful in Children Aged 1-2 Years
by Zacks Equity Research
Vertex Pharmaceuticals' (VRTX) phase III study evaluating Kalydeco in children as young as one year meets its primary safety endpoint.
Varian Halcyon Gets ANVISA Registration, Grows in Oncology
by Zacks Equity Research
Varian (VAR) consistently tries to expand in the global market with Halcyon system.
Genomic Health-Janssen Pharma Tie Up, GPS Test in Focus
by Zacks Equity Research
Genomic Health (GHDX) focuses on notable partnerships to promote its Oncotype DX Genomic Prostate Score (GPS) test.
Myriad Genetics (MYGN) Presents Positive riskScore Test Data
by Zacks Equity Research
Myriad Genetics (MYGN) presents positive riskScore data at the SABCS. With riskScore, the company intends to boost its myRisk Hereditary Cancer test suite.
Hologic's Panther Fusion Flu AdV/hMPV/RV Assay Wins FDA Nod
by Zacks Equity Research
Hologic's (HOLX) recent spree of regulatory approvals for its array of products is encouraging.
Chemed Banks on Roto-Rooter Sales, Focuses on Vitas Revival
by Zacks Equity Research
Chemed (CHE) continues to display robust performance in Roto-Rooter business on strength in core plumbing and drain cleaning service segments.
Walgreens Boots Invests in China to Fortify Retail Pharmacy
by Zacks Equity Research
Walgreens Boots' (WBA) decision to buy a minority stake in Sinopharm Holding Guoda Drugstores is likely to leverage its global pharmacy expertise.
Edwards Lifesciences Buys Harpoon Medical, Expands Portfolio
by Zacks Equity Research
Edwards Lifesciences (EW) expands Surgical Heart Valve Therapy segment with the buyout of Harpoon Medical.
Hologic Banks on Molecular Diagnostics, Competition Rife
by Zacks Equity Research
Hologic (HOLX) gains on increasing market share and utilization of fully-automated Panther system.
Veeva Systems (VEEV) Beats on Earnings in Q3, Updates View
by Zacks Equity Research
Veeva Systems (VEEV) witnesses year-over-year growth in revenues on strength in subscription and professional services in Q3.
Here's Why You Should Invest in PetMed (PETS) Stock Now
by Zacks Equity Research
PetMed's (PETS) implements strategies to revitalize top line. It also offers a comprehensive portfolio.
IDEXX Laboratories Banks on Global Prospects, CAG Strength
by Zacks Equity Research
IDEXX Laboratories (IDXX) rides on strength across all segments, especially CAG. Strong fundamentals buoy optimism.
Align Technology Rides High on InvisAlign & Strategic Pacts
by Zacks Equity Research
Rising demand for InvisAlign products in the global teen market and the distribution agreement with Patterson Dental are major upsides for Align (ALGN).
The Zacks Analyst Blog Highlights: CVS Health, Aetna, PetMed Express, Align Technology and Myriad Genetics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: CVS Health, Aetna, PetMed Express, Align Technology and Myriad Genetics
Quest Diagnostics Banks on Buyouts to Expand in Diagnostic
by Zacks Equity Research
Quest Diagnostics (DGX) actively pursues merger and acquisitions to solidify hold in the high-potential diagnostic information services market. Notably, Cleveland HeartLab buyout marks as the latest deal.
Patterson Companies-SprintRay Deal to Boost Dental Unit
by Zacks Equity Research
Patterson Companies (PDCO) focuses on acquisitions to boost dental segment.
CVS Health's Aetna Buyout to Change Healthcare Landscape
by Zacks Equity Research
Once the Aetna deal is through, CVS Health (CVS) expects to draw $750 million from near-term synergies with low to mid-single digit accretion in the second year.
Cooper Companies' (COO) CooperVision Buys Paragon for $80M
by Zacks Equity Research
The Cooper Companies (COO) focuses on strategic acquisitions to drive inorganic growth.
Boston Scientific (BSX) Shares Drop on LOTUS Relaunch Delay
by Zacks Equity Research
Boston Scientific (BSX) announces a delay in deadline for the commercial return of the LOTUS Edge Aortic Valve System in Europe. Following this news, share price declines.
BioTelemetry's (BEAT) Telcare Unit Collaborates With Onduo
by Zacks Equity Research
BioTelemetry (BEAT) progresses with deals to strengthen hold in the high-potential diabetes care market.
ResMed (RMD) Rides on Innovation Amid Reimbursement Woes
by Zacks Equity Research
ResMed (RMD) achieves strong global revenue growth for the past few quarters on the back of sales of sleep devices, respiratory care devices, mask systems and software solutions.